Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cells

Department für Pädiatrie, Medizinische Universität Innsbruck0 个研究点目标入组 180 人开始时间: 2009年3月30日最近更新: 2021年10月8日

试验速览

暂无简介。

•Patients listed for renal transplantation:
•Patients with renal failure (meeting the criterias for transplantion listing; renal failure stage 4 or 5, glomerular filtration rate < 29ml/min/1.73m2); age 24 months to 80 years; routine VZV vaccination (Varivax)
•Healthy subjects (according to WHO definition): age 24 months to 80 years; routine VZV vaccination with Varivax
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients listed for renal transplantation:
•Positive VZV IgG antibody levels at time point 0; immunosuppression at time of vaccinations; malignancies; rheumatic diseases; loss of immunoglobulins; proteinuria; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy (validated by urine beta-HCG)
•Healthy subjects: Positive VZV IgG antibody levels at time point 0; malignancies; rheumatic diseases; immunosuppression; cortisone therapy in the last 6 months; cytostatic therapy; blood transfusion or treatment with intravenous immunglobulin or plasma products in the last 6 months; pregnancy

发起方

Department für Pädiatrie, Medizinische Universität Innsbruck